SLC5A2 and diabetic kidney disease: Additionally, the recent introduction of Sodium-glucose cotransporter 2 (SGLT2) inhibitors, such as dapagliflozin, has shown promise in treating patients with advanced diabetic kidney disease because of their glucose-lowering effects and benefits on renal outcomes [141].